Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in
cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The
Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe
in the Dose Escalation in combination with a PD-1 checkpoint blockade.